Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease

Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease

Abstract Alzheimer’s disease (AD), the leading cause of dementia, is a multifaceted neurodegenerative disorder characterized by amyloid-beta (Aβ) aggregation, tau pathology, and neuroinflammation. Recent advances in immunotherapy have yielded monoclonal antibodies (mAbs) with unprecedented precision...

Full description

Saved in:
Bibliographic Details
Main Authors: Taha basit Ameen, Umair Ali, Omme Salma, Muhammad Abdul Samee, Syed Muhammad Iraj Abbas, Syeda Naveera Kashif, Muhammad Arif Arifi, Mashooque Ali, Maher Khowaja, Syed Muhammad Sinaan Ali, Abdul Raheem
Format: Article
Language:English
Published: SpringerOpen 2025-05-01
Series:The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Subjects:
Alzheimer’s disease
Amyloid-beta
Monoclonal antibodies
Immunotherapy
Lecanemab
Donanemab
Online Access:https://doi.org/10.1186/s41983-025-00968-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s41983-025-00968-3

Similar Items